Comparison
3 Phosphoglycerate Dehydrogenase Deficiency C0580190 vs 3m Syndrome 1 C2678312
Clinical comparison between 3 Phosphoglycerate Dehydrogenase Deficiency and 3M Syndrome 1 for differential diagnosis and treatment planning.
3 Phosphoglycerate Dehydrogenase Deficiency C0580190
A rare metabolic disorder impairing the body's ability to produce serine, an essential amino acid. It primarily affects the nervous system, causing developmental delay, seizures, and movement difficulties. Management includes serine supplementation and anticonvulsants as needed.
3m Syndrome 1 C2678312
A genetic disorder causing severe short stature with distinctive facial features and skeletal abnormalities. Management involves monitoring growth and addressing orthopedic or other associated concerns.
6 comparison axes
Onset
3 Phosphoglycerate Dehydrogenase Deficiency C0580190
0-5
3m Syndrome 1 C2678312
0-0
Onset patterns differ
Severity
3 Phosphoglycerate Dehydrogenase Deficiency C0580190
severe
3m Syndrome 1 C2678312
moderate
Different severity levels
Chronic
3 Phosphoglycerate Dehydrogenase Deficiency C0580190
Chronic
3m Syndrome 1 C2678312
Chronic
Differing course
Communicable
3 Phosphoglycerate Dehydrogenase Deficiency C0580190
No
3m Syndrome 1 C2678312
No
Different transmission
Body System
3 Phosphoglycerate Dehydrogenase Deficiency C0580190
metabolic
3m Syndrome 1 C2678312
musculoskeletal
Same/different system
Category
3 Phosphoglycerate Dehydrogenase Deficiency C0580190
metabolic
3m Syndrome 1 C2678312
genetic
Different category
Bottom line
3-phosphoglycerate-dehydrogenase-deficiency-C0580190 and 3m-syndrome-1-C2678312 differ in severity, etiology
Key differentiating points
Findings that most reliably separate the two conditions at the bedside or in the workup.
| Feature | 3 Phosphoglycerate Dehydrogenase Deficiency C0580190 | 3m Syndrome 1 C2678312 | Discriminating power |
|---|---|---|---|
| Neurologic features | Developmental delay, seizures, and movement difficulty are described. | Neurologic disease is not the defining supplied feature. | High |
| Growth and skeleton | Severe short stature and skeletal anomalies are not the primary description. | Severe short stature, distinctive facial features, and skeletal abnormalities are described. | High |
| Onset pattern | Source onset range is early childhood, coded 0–5 years. | Source onset is coded at birth, 0–0. | Moderate |
When to favor each condition
Choose 3 Phosphoglycerate Dehydrogenase Deficiency C0580190 when
Early seizures with developmental delay
This pattern aligns with the described neurologic metabolic disorder, but confirmation is required.
Moderate
Suspected impaired serine production
The source classifies it as a metabolic disorder affecting serine synthesis.
Moderate
Metabolic evaluation is prioritized
The assigned body system is metabolic rather than musculoskeletal.
Moderate
Choose 3m Syndrome 1 C2678312 when
Congenital severe short stature
Growth impairment and birth-coded onset match the supplied syndrome description.
Moderate
Facial and skeletal abnormalities
These features are specifically described for 3M syndrome 1.
Moderate
Orthopedic monitoring is central
Source management emphasizes growth surveillance and orthopedic concerns.
Moderate
How key tests differ
| Test | 3 Phosphoglycerate Dehydrogenase Deficiency C0580190 | 3m Syndrome 1 C2678312 | Interpretation |
|---|---|---|---|
| Amino acid analysis | Low serine may be sought; no cutoff is established here. | Not described as the defining test. | An abnormal result supports evaluation but does not alone establish either diagnosis. |
| Genetic testing | May investigate variants relevant to serine synthesis. | May investigate variants associated with 3M syndrome 1. | Results require clinical correlation and specialist interpretation. |
| Growth and skeletal assessment | Not the primary discriminator in the source. | May document short stature and skeletal abnormalities. | Imaging or measurements support phenotype but are not a standalone diagnosis. |
Prognosis comparison
3 Phosphoglycerate Dehydrogenase Deficiency C0580190
- Outcome
- Source severity is severe and course chronic, but individual outcome is not established.
- Factors
- Neurologic features, seizure burden, developmental support, and confirmed diagnosis may matter.
3m Syndrome 1 C2678312
- Outcome
- Source severity is moderate and course chronic, centered on growth and skeleton.
- Factors
- Growth pattern, skeletal findings, and associated clinical needs may influence outcome.
Time frame: Both are described as chronic; no reliable survival estimate is available here.
Severity and etiology differ, but prognosis must be individualized by clinicians.
Complications comparison
| Complication | Presentation |
|---|---|
| Seizures | Seizures are described and may need anticonvulsant care. Not listed as a core feature. New seizures warrant neurologic assessment rather than assumption of either condition. |
| Skeletal complications | Not the main described burden. Skeletal abnormalities may require monitoring or orthopedic care. Specific complications and interventions are not established by this source. |
| Developmental impact | Developmental delay is a described feature. Developmental outcome is not specified as primary. Early developmental assessment may still be appropriate when concerns exist. |
Patient education highlights
- HighDifferent conditions
One is a metabolic neurologic disorder; the other is a genetic growth and skeletal syndrome.
- MediumTesting limits
An abnormal laboratory or imaging result is not itself a diagnosis and needs clinician review.
- LowTreatment caution
Do not start supplements or medicines without specialist advice; doses are not provided here.